Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

CG Oncology (CGON) EBIT: 2023-2024

Historic EBIT for CG Oncology (CGON) over the last 2 years, with Dec 2024 value amounting to -$114.7 million.

  • CG Oncology's EBIT fell 80.70% to -$51.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$180.1 million, marking a year-over-year decrease of 87.68%. This contributed to the annual value of -$114.7 million for FY2024, which is 106.80% down from last year.
  • According to the latest figures from FY2024, CG Oncology's EBIT is -$114.7 million, which was down 106.80% from -$55.4 million recorded in FY2023.
  • CG Oncology's EBIT's 5-year high stood at -$55.4 million during FY2023, with a 5-year trough of -$114.7 million in FY2024.
  • Its 2-year average for EBIT is -$85.1 million, with a median of -$85.1 million in 2023.
  • Data for CG Oncology's EBIT shows a maximum YoY crashed of 106.80% (in 2024) over the last 5 years.
  • Over the past 2 years, CG Oncology's EBIT (Yearly) stood at -$55.4 million in 2023, then tumbled by 106.80% to -$114.7 million in 2024.